<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="as 370 million people. This paper explores current methods of" exact="strongyloidiasis" post="treatment, which rely on administration of anthelminthic drugs. However"/>
 <result pre="to control animal and human parasitic nematodes in the environment." exact="strongyloidiasis" post="Strongyloides stercoralis anthelminthic drugs nematicides ivermectin resistance 1. Introduction"/>
 <result pre="stercoralis life-cycle, insensitivity of detection methods and social factors challenge" exact="strongyloidiasis" post="identification, diagnosis and treatment [3,13]. If not diagnosed in"/>
 <result pre="given that we see high disease rates in population sub-groups," exact="strongyloidiasis" post="is not only a personal but a public health"/>
 <result pre="lungs [16,17]. The repeated cycle of this leads to pulmonary" exact="strongyloidiasis" post="[18]. There are no further studies done showing the"/>
 <result pre="larvae maturing into adult worm in the lungs. The pulmonary" exact="strongyloidiasis" post="is believed to occur due to autoinfection and filariform"/>
 <result pre="main constituents, mode of action and toxic effects. To date," exact="strongyloidiasis" post="treatment has tended to be viewed only from a"/>
 <result pre="for drug resistance. Here we suggest a combined approach of" exact="strongyloidiasis" post="treatment; through clinical intervention with drugs once infection has"/>
 <result pre="it has been demonstrated to have a suboptimal effect against" exact="strongyloidiasis" post="(Table 1) [24]. Ivermectin has been shown to be"/>
 <result pre="the most effective and therefore the first choice drug in" exact="strongyloidiasis" post="treatment [25], especially for chronic strongyloidiasis [26,27]. 2.1. Benzimidazoles"/>
 <result pre="first choice drug in strongyloidiasis treatment [25], especially for chronic" exact="strongyloidiasis" post="[26,27]. 2.1. Benzimidazoles (Albendazole and Mebendazole) Benzimidazole is a"/>
 <result pre="nematode paralysis [36,37]. Ivermectin is currently the best treatment for" exact="onchocerciasis" post="and administered at intervals of one year in highly"/>
 <result pre="ability of ivermectin, its oral administration can be impaired in" exact="strongyloidiasis" post="disseminated patients. There is, however, no parenteral administration of"/>
 <result pre="ivermectin licensed currently, which is essential in cases of disseminated" exact="strongyloidiasis" post="[39,40]. 2.3. Anthelminthic Drugs Associated Issues Treatment of soil-transmitted"/>
 <result pre="strongyloidiasis [39,40]. 2.3. Anthelminthic Drugs Associated Issues Treatment of soil-transmitted" exact="helminthiasis" post="is challenging due to development of resistance, as demonstrated"/>
 <result pre="veterinary practice, and reinfection occurrence [41,42]. Among soil-transmitted helminth infections," exact="strongyloidiasis" post="is the most difficult to treat because of its"/>
 <result pre="sensitivity and accuracy, and should be used for not only" exact="strongyloidiasis" post="diagnosis but also follow-up tests [48,49]. The drugs, while"/>
 <result pre="pregnant women who have a high risk of developing iron-deficiency" exact="anemia" post="[54]. Animal-infecting nematode resistance development results in need for"/>
 <result pre="family over the years, as in case of ivermectin against" exact="strongyloidiasis" post="[60]. Studies on benzimidazole drugs against human nematodes have"/>
 <result pre="parasite [60]. A human immune system changes in response to" exact="strongyloidiasis" post="infection, in particular T and B cells. The immune"/>
 <result pre="drugs allows integrating control programs for intestinal helminth infections, lymphatic" exact="filariasis" post="and onchocerciasis with schistosomiasis and food-borne trematode infections. However,"/>
 <result pre="integrating control programs for intestinal helminth infections, lymphatic filariasis and" exact="onchocerciasis" post="with schistosomiasis and food-borne trematode infections. However, MDA could"/>
 <result pre="programs for intestinal helminth infections, lymphatic filariasis and onchocerciasis with" exact="schistosomiasis" post="and food-borne trematode infections. However, MDA could be associated"/>
 <result pre="non-existent in human parasite control. An overlooked environmental approach in" exact="strongyloidiasis" post="control is to kill free-living parasites in environment before"/>
 <result pre="Above we have assessed commercially available drugs used to treat" exact="strongyloidiasis" post="and explored the main issues associated with these drug"/>
 <result pre="used on free-living Strongyloides nematodes. A combined approach to fight" exact="strongyloidiasis" post="should consider environmental control as well as drug treatment."/>
 <result pre="group, against the root-knot nematode meloidogyne javanicaPest Manag. Sci.2009651082108910.1002/ps.179619488996 19.NamisatoS.MotomuraK.HaranagaS.HirataT.ToyamaM.ShinzatoT.HigaF.SaitoA.Pulmonary" exact="strongyloidiasis" post="in a patient receiving prednisolone therapyIntern. Med.20044373173610.2169/internalmedicine.43.73115468976 20.GarrardT.A.RossK.E.TaylorM.J.Biocontrol for"/>
 <result pre="on the efficacy of three anthelmintics on treatment of human" exact="strongyloidiasis" post="in okinawa, JapanSoutheast Asian J. Trop. Med. Public Health20003114715111023084"/>
 <result pre="of veterinary importance: A status reportTrends Parasitol.20042047748110.1016/j.pt.2004.08.00115363441 43.PaulaF.Costa-CruzJ.Epidemiological aspects of" exact="strongyloidiasis" post="in brazilParasitology2011138133110.1017/S003118201100120X21810305 44.VadlamudiR.S.ChiD.S.KrishnaswamyG.Intestinal strongyloidiasis and hyperinfection syndromeClin. Mol. Allergy20064110.1186/1476-7961-4-816478539"/>
 <result pre="status reportTrends Parasitol.20042047748110.1016/j.pt.2004.08.00115363441 43.PaulaF.Costa-CruzJ.Epidemiological aspects of strongyloidiasis in brazilParasitology2011138133110.1017/S003118201100120X21810305 44.VadlamudiR.S.ChiD.S.KrishnaswamyG.Intestinal" exact="strongyloidiasis" post="and hyperinfection syndromeClin. Mol. Allergy20064110.1186/1476-7961-4-816478539 45.ScowdenE.B.SchaffnerW.StoneW.J.Overwhelming strongyloidiasis: An unappreciated"/>
 <result pre="infectionPLoS Negl. Trop. Dis.20159e000349110.1371/journal.pntd.000349125668740 50.ShikiyaK.ZahaO.NiimuraS.UeharaT.OhshiroJ.KinjoF.SaitoA.AsatoR.[clinical study on ivermectin against 125" exact="strongyloidiasis" post="patients]Kansenshogaku Zasshi199468132010.11150/kansenshogakuzasshi1970.68.138138669 51.ZahaO.HirataT.KinjoF.SaitoA.FukuharaH.Efficacy of ivermectin for chronic strongyloidiasis: Two"/>
 <result pre="Two single doses given 2 weeks apartJ. Infect. Chemother.20028949810.1007/s10156020001311957127 52.LichtenbergerP.Rosa-CunhaI.MorrisM.NishidaS.AkpinarE.GaitanJ.TzakisA.Doblecki-LewisS.Hyperinfection" exact="strongyloidiasis" post="in a liver transplant recipient treated with parenteral ivermectinTranspl."/>
</results>
